The activation or depletion of TIL-B phenotypes correlates with CD4 + T cell phenotypes and is associated with improved clinical outcomes in NSCLC patients, showcasing elevated TME activation and enhanced TIL-B antigen presentation [59]. The gene discussed is CD4; the disease is non-small cell lung carcinoma.